Shares of Mirum Pharmaceuticals (MIRM) were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025.Mirum’s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progres ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Mirum Pharmaceuticals: Transforming Lives in Rare Disease J a n u a r y 2 0 2 5 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to managem include all statements other than statements of historical fact contained in this presentation, including information concerning our business strategy, objectives and oppor opportunities for LIVMARLI, CHOLBAM, chenodiol, and Mirum's clinica ...

Core Insights - The Fortune Teller is a team of two analysts with over 30 years of combined market experience [1] - The team includes a former licensed investment advisor with a background in asset management, holding degrees in Accounting & Economics and Computer Sciences, as well as MBAs [1] - They lead the investing group Wheel of Fortune, which shares actionable trading ideas across various asset classes, sectors, and industries [1] Service Features - The service aims to provide a comprehensive resource for investment and portfolio ideas while educating subscribers [1] - It includes the Funds Macro Portfolio, focusing on ETFs and CEFs for less active investors [1] - The Single Macro Portfolio is designed for more active investors, focusing on single equity [1] - Additional offerings include educational content and a live chat room for discussions among investors and The Fortune Teller [1]

Mirum has 3 approved products – LIVMARLI, cholbam and chenodal. LIVMARLI, or maralixibat, is an inhibitor of ileal bile acid transporter, andMirum Pharmaceuticals (NASDAQ: MIRM ) is a liver and rare disease franchise I used to own and cover earlier. I covered it last over a year ago.About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any t ...

A month has gone by since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM) . Shares have lost about 0.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Mirum's Q3 Earnings & Re ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahe ...

Core Viewpoint - Mirum Pharmaceuticals reported a narrower loss per share in Q3 2024 compared to estimates, with significant revenue growth driven by product sales and acquisitions [1][2]. Financial Performance - The company incurred a loss of 30 cents per share in Q3 2024, better than the Zacks Consensus Estimate of a loss of 45 cents, and an improvement from a loss of 57 cents per share in the same quarter last year [1]. - Revenues for the third quarter reached $90.3 million, marking an 89% increase year over year, surpassing the Zacks Consensus Estimate of $82 million [2]. - Livmarli's net product sales were $59.1 million, reflecting a 52.7% year-over-year increase, while newly acquired Cholbam and Chenodal contributed $31.2 million [4]. - Research and development expenses rose by 21.5% year over year to $31.7 million, and selling, general and administrative expenses increased by 38.3% to $50.5 million [4][5]. Guidance and Future Outlook - Mirum has raised its 2024 revenue guidance to a range of $330-$335 million, up from the previous estimate of $310-$320 million [6]. - The company initiated the phase III EXPAND study for Livmarli, aiming for label expansion in cholestatic pruritus [7]. Product Developments - Livmarli received European Commission approval for treating progressive familial intrahepatic cholestasis (PFIC) in patients aged three months and older [7]. - The FDA approved a label expansion for Livmarli to include treatment for cholestatic pruritus in patients aged five years and older with PFIC [8]. - Mirum's pipeline candidate, volixibat, is under evaluation in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with Breakthrough Therapy designation granted by the FDA [9]. Recent Acquisitions - Mirum acquired Travere Therapeutics' bile acid products, adding Cholbam and Chenodal to its portfolio [2]. - The company in-licensed a PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome, with a phase II study expected to begin in 2025 [10]. Stock Performance - Shares of Mirum rose in pre-market trading due to better-than-expected results and increased guidance, with a year-to-date stock rally of 40.9% compared to a 1.2% decline in the industry [3].

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.52, delivering a surprise of -8.33%.Over the last four quarters, the company ...

It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM) . Shares have added about 4.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Mirum Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Mirum's Q2 Earning ...